Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer

被引：0
|
作者：
Yue Xi
Ting Li
Yun Xi
Xinyi Zeng
Ying Miao
Rui Guo
Min Zhang
Biao Li
机构：
[1] Ruijin Hospital,Department of Nuclear Medicine
[2] Shanghai Jiao Tong University School of Medicine,Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics
[3] Collaboration Innovation Center for Molecular Imaging of Precision Medicine,undefined
[4] Ruijin Center,undefined
[5] National Research Center for Translational Medicine at Shanghai,undefined
[6] Ruijin Hospital,undefined
[7] Shanghai Jiao Tong University School of Medicine,undefined
来源：
Cancer Cell International | / 22卷
关键词：
Triple-negative breast cancer; hENT1; miR-143; Combination therapy; Gemcitabine resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
    Xi, Yue
    Li, Ting
    Xi, Yun
    Zeng, Xinyi
    Miao, Ying
    Guo, Rui
    Zhang, Min
    Li, Biao
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [2] WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition
    Wang, Ruquan
    Li, Yongliang
    Gao, Jianjun
    Luan, Yepeng
    DRUG DISCOVERIES AND THERAPEUTICS, 2022, 16 (06): : 286 - 292
  • [3] Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
    Li, Xinyang
    Yuan, Xiang
    Wang, Ziming
    Li, Jing
    Liu, Zhiwei
    Wang, Yukun
    Wei, Limin
    Li, Yuanpei
    Wang, Xinshuai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Loss of miR-873 contributes to gemcitabine resistance in triple-negative breast cancer via targeting ZEB1
    Wang, Gangyue
    Dong, Yi
    Liu, Heng
    Ji, Nan
    Cao, Jilei
    Liu, Aihui
    Tang, Xin
    Ren, Yu
    ONCOLOGY LETTERS, 2019, 18 (04) : 3837 - 3844
  • [5] Involvement of miR-99a in resistance to chemotherapy in triple-negative breast cancer
    Garrido-Cano, I.
    Pattanayak, B.
    Adam-Artigues, A.
    Cabello, P.
    Pineda, B.
    Tormo, E.
    Albanell, J.
    Rojo, F.
    Lluch, A.
    Eroles, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 32 - 32
  • [6] Gemcitabine with cisplatin or paclitaxel in metastatic triple-negative breast cancer
    Hu, Xichun
    Xu, Binghe
    Cai, Li
    Wang, Zhonghua
    Wang, Biyun
    Zhang, Jian
    Teng, Yuee
    Tong, Zhongsheng
    Pan, Yueyin
    Yin, Yongmei
    Wu, Changping
    Jiang, Zefei
    Wang, Xiaojia
    Lou, Guyin
    Liu, Donggeng
    Feng, Jifeng
    Luo, Jianfeng
    Wu, Jiong
    Shao, Zhimin
    Ragaz, Joseph
    CANCER RESEARCH, 2015, 75
  • [7] The inhibitory effects of lobaplatin, or in combination with gemcitabine on triple-negative breast cancer cells in vitro and in vivo
    Jiang, Chengyan
    Zhang, Ye
    Xu, Xiaoyu
    Su, Shanshan
    Pan, Huafeng
    Jiang, Aiqin
    ONCOLOGIE, 2023, 25 (01) : 81 - 91
  • [8] Targeting EGFR reverses paclitaxel resistance associated with ABCB1 overexpression in triple-negative breast cancer
    Ahmadzadeh, Elaheh
    Przybytkowski, Ewa
    Aguilar-Mahecha, Adriana
    Basik, Mark
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [9] Knockdown ofSERPINE1reverses resistance of triple-negative breast cancer to paclitaxel via suppression ofVEGFA
    Zhang, Qian
    Lei, Li
    Jing, Di
    ONCOLOGY REPORTS, 2020, 44 (05) : 1875 - 1884
  • [10] Potential Combination Therapy for Triple-Negative Breast Cancer
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (06) : 1279 - 1279
12345